Cargando…

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients

BACKGROUND: In metastatic breast cancer (MBC), antigen profiles of metastatic tissue and primary tumor differ in up to 20 % of patients. Reassessment of predictive markers, including human epidermal growth factor receptor 2 (HER2) expression, might help to optimize MBC treatment. While tissue sampli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wallwiener, Markus, Hartkopf, Andreas Daniel, Riethdorf, Sabine, Nees, Juliane, Sprick, Martin Ronald, Schönfisch, Birgitt, Taran, Florin-Andrei, Heil, Jörg, Sohn, Christof, Pantel, Klaus, Trumpp, Andreas, Schneeweiss, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435916/ https://www.ncbi.nlm.nih.gov/pubmed/25972110 http://dx.doi.org/10.1186/s12885-015-1423-6

Ejemplares similares

Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients
por: Wallwiener, Markus, et al.
Publicado: (2014)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients
por: Hartkopf, Andreas D., et al.
Publicado: (2016)

Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients
por: Hartkopf, Andreas D, et al.
Publicado: (2017)

The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer
por: Stefanovic, Stefan, et al.
Publicado: (2020)

How previous treatment changes the metabolomic profile in patients with metastatic breast cancer
por: Nees, Juliane, et al.
Publicado: (2022)

Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center
por: Taran, Florin Andrei, et al.
Publicado: (2023)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
por: Hartkopf, Andreas Daniel, et al.
Publicado: (2013)

Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
por: Stefanovic, Stefan, et al.
Publicado: (2019)

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
por: Matthies, Lina Maria, et al.
Publicado: (2019)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial
por: Wallwiener, Markus, et al.
Publicado: (2017)

Fertility preserving management of early endometrial cancer in a patient cohort at the department of women’s health at the university of Tuebingen
por: Andress, Jürgen, et al.
Publicado: (2021)

Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence
por: Cheng, Jie, et al.
Publicado: (2017)

Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
por: Volmer, Léa L., et al.
Publicado: (2023)

Heterogeneity of miR-10b expression in circulating tumor cells
por: Gasch, Christin, et al.
Publicado: (2015)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study
por: Brusniak, Katharina, et al.
Publicado: (2021)

Parity improves anti-tumor immunity in breast cancer patients
por: Krause, Anna-Lena, et al.
Publicado: (2017)

Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle
por: Stefanovic, Stefan, et al.
Publicado: (2020)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
por: Taran, Florin-Andrei, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial
por: von Au, Alexandra, et al.
Publicado: (2016)

Clinical relevance and current challenges of research on disseminating tumor cells in cancer patients
por: Riethdorf, Sabine, et al.
Publicado: (2009)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
por: Fischer, Chiara, et al.
Publicado: (2022)

Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
por: Fischer, Chiara, et al.
Publicado: (2022)

Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Recurrence Score(®) Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
por: Dannehl, Dominik, et al.
Publicado: (2022)

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0n2cvbb5el2hudkfe6q5s1eru1